TP53 and neoplasm: This initiative enabled the current study which focused on the clinical significance of the tumour suppressor protein (TP53) beta-isoform (β) variant, NM_001126114.3, c.1018A>G, p.N340D, described by Leroy et al. (2017) in tumour-extracted DNA [8].